NeuroSense Therapeutics Ltd

XNAS:NRSN 3:59:57 PM EDT

3.17

+0.11 (+3.60%)

6:33:36 PM EDT: $3.04 -0.13 (-3.96%)

Market Cap (Intraday)	6.01M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.54 Million
Adjusted EPS	-$0.79

See more estimates

10-Day MA	$3.65
50-Day MA	$6.72
200-Day MA	$13.68

See more pivots

NeuroSense Therapeutics Ltd Stock, XNAS:NRSN

11 HaMenofim Street, Building B, Herzliya, Tel Aviv 46725

Israel

Phone: +972.9.799.6183

Number of Employees: 18

http://www.neurosense-tx.com

Description

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. It is involved in the 2b/3 clinical trial using its product candidate, PrimeC in patients with ALS and also commencing research into other possible indications for the drug, including AlzheimerÃ¢â?¬â?¢s and ParkinsonÃ¢â?¬â?¢s diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.